Keymed Biosciences (HKG:2162) raised net proceeds of HK$853.8 million through a top-up placement, a Thursday Hong Kong bourse filing said.
21.6 million shares were placed by substantial shareholder Moonshot at HK$45.48 apiece to at least six investors.
The biopharmaceutical firm then issued 19 million shares to Moonshot, representing 6.36% of its enlarged issued share capital.
The drug company will use proceeds from the issue for R&D expenses, commercialization of Stapokibart, the capital expenditure of manufacturing and R&D facilities, and general corporate and working capital.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.